Basel, 30 September 2019 FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vasculitis in children are rare and associated with severe,... Read more
Basel, 30 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more
Basel, 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival... Read more
Basel, 27 September 2019 Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data will be shared with health authorities... Read more
Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more
Basel, 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay... Read more
Basel, 20 September 2019 FDA approves cobas Babesia, Roche’s first whole blood test for donor screening Roche is dedicated to helping save patients’ lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infection can be fatal in patients receiving blood transfusions from infected... Read more
Basel, 19 September 2019 Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world’s first comprehensive primary healthcare facility on rail Phelophepa has touched the lives of over 14 million people... Read more
Basel, 18 September 2019 FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal... Read more
Basel, 16 September 2019 Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running Roche ranked second in the 2019 Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Compared to 2018 Roche significantly... Read more